Annual CFF
$283.90 K
+$778.80 K+157.37%
31 December 2023
Summary:
Oragenics annual cash flow from financing activities is currently $283.90 thousand, with the most recent change of +$778.80 thousand (+157.37%) on 31 December 2023. During the last 3 years, it has fallen by -$22.86 million (-98.77%). OGEN annual CFF is now -98.78% below its all-time high of $23.25 million, reached on 31 December 2018.OGEN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.77 M
+$2.94 M+358.56%
30 September 2024
Summary:
Oragenics quarterly cash flow from financing activities is currently $3.77 million, with the most recent change of +$2.94 million (+358.56%) on 30 September 2024. Over the past year, it has increased by +$3.95 million (+2185.11%). OGEN quarterly CFF is now -83.76% below its all-time high of $23.19 million, reached on 31 March 2021.OGEN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$6.06 M
+$3.03 M+100.27%
30 September 2024
Summary:
Oragenics TTM cash flow from financing activities is currently $6.06 million, with the most recent change of +$3.03 million (+100.27%) on 30 September 2024. Over the past year, it has increased by +$5.78 million (+2034.95%). OGEN TTM CFF is now -84.72% below its all-time high of $39.65 million, reached on 30 June 2021.OGEN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OGEN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +2185.1% | +2035.0% |
| 3 y3 years | -98.8% | +2206.1% | -73.8% |
| 5 y5 years | -97.4% | +5216.4% | -45.4% |
OGEN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -98.8% | +157.4% | at high | +2178.2% | -73.8% | +1134.5% |
| 5 y | 5 years | -98.8% | +157.4% | -83.8% | +2178.2% | -84.7% | +1134.5% |
| alltime | all time | -98.8% | +157.4% | -83.8% | +2178.2% | -84.7% | +1134.5% |
Oragenics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.77 M(+358.6%) | $6.06 M(+100.3%) |
| June 2024 | - | $821.20 K(-50.3%) | $3.03 M(+44.3%) |
| Mar 2024 | - | $1.65 M(-1015.1%) | $2.10 M(+638.7%) |
| Dec 2023 | $283.90 K(-157.4%) | -$180.60 K(-124.7%) | $283.80 K(-24.6%) |
| Sept 2023 | - | $732.10 K(-778.5%) | $376.40 K(-182.0%) |
| June 2023 | - | -$107.90 K(-32.5%) | -$459.20 K(-3.0%) |
| Mar 2023 | - | -$159.80 K(+81.6%) | -$473.50 K(-4.3%) |
| Dec 2022 | -$494.90 K(-102.1%) | -$88.00 K(-15.0%) | -$494.90 K(-15.5%) |
| Sept 2022 | - | -$103.50 K(-15.3%) | -$585.70 K(+16.2%) |
| June 2022 | - | -$122.20 K(-32.6%) | -$504.10 K(+119.6%) |
| Mar 2022 | - | -$181.20 K(+1.3%) | -$229.60 K(-101.0%) |
| Dec 2021 | $23.14 M(+41.8%) | -$178.80 K(+716.4%) | $23.14 M(-33.0%) |
| Sept 2021 | - | -$21.90 K(-114.4%) | $34.55 M(-12.9%) |
| June 2021 | - | $152.30 K(-99.3%) | $39.65 M(+0.2%) |
| Mar 2021 | - | $23.19 M(+106.5%) | $39.59 M(+142.5%) |
| Dec 2020 | $16.32 M(+47.1%) | $11.23 M(+121.0%) | $16.32 M(+225.0%) |
| Sept 2020 | - | $5.08 M(+5563.5%) | $5.02 M(-4799.1%) |
| June 2020 | - | $89.70 K(-222.9%) | -$106.90 K(-67.3%) |
| Mar 2020 | - | -$73.00 K(-0.8%) | -$326.60 K(-102.9%) |
| Dec 2019 | $11.10 M(-52.3%) | -$73.60 K(+47.2%) | $11.10 M(-46.2%) |
| Sept 2019 | - | -$50.00 K(-61.5%) | $20.61 M(-37.6%) |
| June 2019 | - | -$130.00 K(-101.1%) | $33.05 M(-4.6%) |
| Mar 2019 | - | $11.35 M(+20.3%) | $34.64 M(+49.0%) |
| Dec 2018 | $23.25 M(+175.1%) | $9.44 M(-23.8%) | $23.25 M(+26.3%) |
| Sept 2018 | - | $12.39 M(+746.3%) | $18.41 M(+124.6%) |
| June 2018 | - | $1.46 M(-3618.0%) | $8.20 M(-2.6%) |
| Mar 2018 | - | -$41.60 K(-100.9%) | $8.41 M(-0.4%) |
| Dec 2017 | $8.45 M(+89.8%) | $4.60 M(+111.7%) | $8.45 M(+76.5%) |
| Sept 2017 | - | $2.17 M(+29.5%) | $4.79 M(+34.4%) |
| June 2017 | - | $1.68 M(<-9900.0%) | $3.56 M(-20.5%) |
| Mar 2017 | - | -$5000.00(-100.5%) | $4.48 M(+0.6%) |
| Dec 2016 | $4.45 M(-2882.2%) | $939.40 K(-1.1%) | $4.45 M(+28.4%) |
| Sept 2016 | - | $949.90 K(-63.4%) | $3.47 M(+39.7%) |
| June 2016 | - | $2.60 M(-7758.1%) | $2.48 M(-1660.8%) |
| Mar 2016 | - | -$33.90 K(-26.6%) | -$159.00 K(-0.6%) |
| Dec 2015 | -$160.00 K(+1.1%) | -$46.20 K(+34.7%) | -$159.90 K(+0.9%) |
| Sept 2015 | - | -$34.30 K(-23.1%) | -$158.40 K(-0.1%) |
| June 2015 | - | -$44.60 K(+28.2%) | -$158.60 K(0.0%) |
| Mar 2015 | - | -$34.80 K(-22.1%) | -$158.60 K(+0.3%) |
| Dec 2014 | -$158.20 K(-101.2%) | -$44.70 K(+29.6%) | -$158.20 K(-101.7%) |
| Sept 2014 | - | -$34.50 K(-22.6%) | $9.12 M(-30.0%) |
| June 2014 | - | -$44.60 K(+29.7%) | $13.03 M(-0.5%) |
| Mar 2014 | - | -$34.40 K(-100.4%) | $13.09 M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | $13.13 M(-12.3%) | $9.23 M(+138.1%) | $13.13 M(+243.4%) |
| Sept 2013 | - | $3.88 M(>+9900.0%) | $3.83 M(-67.5%) |
| June 2013 | - | $23.80 K(+349.1%) | $11.75 M(-9.9%) |
| Mar 2013 | - | $5300.00(-106.6%) | $13.04 M(-12.9%) |
| Dec 2012 | $14.98 M(+170.6%) | -$79.80 K(-100.7%) | $14.98 M(-9.9%) |
| Sept 2012 | - | $11.81 M(+799.5%) | $16.62 M(+162.4%) |
| June 2012 | - | $1.31 M(-32.3%) | $6.33 M(-1.4%) |
| Mar 2012 | - | $1.94 M(+24.1%) | $6.43 M(+16.1%) |
| Dec 2011 | $5.53 M(-13.1%) | $1.56 M(+2.9%) | $5.53 M(+4.8%) |
| Sept 2011 | - | $1.52 M(+8.1%) | $5.28 M(-6.0%) |
| June 2011 | - | $1.40 M(+34.0%) | $5.62 M(+5.3%) |
| Mar 2011 | - | $1.05 M(-19.8%) | $5.34 M(-16.2%) |
| Dec 2010 | $6.37 M(+29.8%) | $1.31 M(-29.6%) | $6.37 M(+5.9%) |
| Sept 2010 | - | $1.86 M(+65.1%) | $6.01 M(+9.9%) |
| June 2010 | - | $1.12 M(-45.9%) | $5.47 M(-21.4%) |
| Mar 2010 | - | $2.08 M(+118.6%) | $6.96 M(+41.8%) |
| Dec 2009 | $4.90 M(+8.1%) | $950.50 K(-27.8%) | $4.90 M(+24.9%) |
| Sept 2009 | - | $1.32 M(-49.5%) | $3.93 M(+51.3%) |
| June 2009 | - | $2.61 M(+9565.6%) | $2.60 M(+1.0%) |
| Mar 2009 | - | $27.00 K(-202.7%) | $2.57 M(-43.4%) |
| Dec 2008 | $4.54 M(+168.3%) | -$26.30 K(+71.9%) | $4.54 M(-0.4%) |
| Sept 2008 | - | -$15.30 K(-100.6%) | $4.56 M(-21.7%) |
| June 2008 | - | $2.58 M(+29.5%) | $5.82 M(+80.2%) |
| Mar 2008 | - | $2.00 M(<-9900.0%) | $3.23 M(+90.8%) |
| Dec 2007 | $1.69 M(-15.4%) | -$7100.00(-100.6%) | $1.69 M(-29.9%) |
| Sept 2007 | - | $1.24 M(<-9900.0%) | $2.41 M(+100.2%) |
| June 2007 | - | -$4300.00(-100.9%) | $1.21 M(-37.7%) |
| Mar 2007 | - | $459.10 K(-35.7%) | $1.94 M(-3.3%) |
| Dec 2006 | $2.00 M(+45.8%) | $713.60 K(+1839.1%) | $2.00 M(+4.9%) |
| Sept 2006 | - | $36.80 K(-94.9%) | $1.91 M(+8.1%) |
| June 2006 | - | $726.40 K(+38.5%) | $1.76 M(+31.9%) |
| Mar 2006 | - | $524.30 K(-15.5%) | $1.34 M(-2.5%) |
| Dec 2005 | $1.37 M(-61.0%) | $620.40 K(-681.4%) | $1.37 M(+4.1%) |
| Sept 2005 | - | -$106.70 K(-135.6%) | $1.32 M(-7.6%) |
| June 2005 | - | $299.30 K(-46.5%) | $1.43 M(+32.1%) |
| Mar 2005 | - | $559.20 K(-1.4%) | $1.08 M(-69.3%) |
| Dec 2004 | $3.52 M(-27.1%) | $566.90 K(>+9900.0%) | $3.52 M(-33.5%) |
| Sept 2004 | - | $1100.00(-102.3%) | $5.29 M(-3.8%) |
| June 2004 | - | -$47.60 K(-101.6%) | $5.50 M(-28.8%) |
| Mar 2004 | - | $3.00 M(+28.2%) | $7.73 M(+60.0%) |
| Dec 2003 | $4.83 M | $2.34 M(+1021.6%) | $4.83 M(+94.0%) |
| Sept 2003 | - | $208.50 K(-90.4%) | $2.49 M(+9.1%) |
| June 2003 | - | $2.18 M(+2080.4%) | $2.28 M(+2180.4%) |
| Mar 2003 | - | $100.00 K | $100.00 K |
FAQ
- What is Oragenics annual cash flow from financing activities?
- What is the all time high annual CFF for Oragenics?
- What is Oragenics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Oragenics?
- What is Oragenics quarterly CFF year-on-year change?
- What is Oragenics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Oragenics?
- What is Oragenics TTM CFF year-on-year change?
What is Oragenics annual cash flow from financing activities?
The current annual CFF of OGEN is $283.90 K
What is the all time high annual CFF for Oragenics?
Oragenics all-time high annual cash flow from financing activities is $23.25 M
What is Oragenics quarterly cash flow from financing activities?
The current quarterly CFF of OGEN is $3.77 M
What is the all time high quarterly CFF for Oragenics?
Oragenics all-time high quarterly cash flow from financing activities is $23.19 M
What is Oragenics quarterly CFF year-on-year change?
Over the past year, OGEN quarterly cash flow from financing activities has changed by +$3.95 M (+2185.11%)
What is Oragenics TTM cash flow from financing activities?
The current TTM CFF of OGEN is $6.06 M
What is the all time high TTM CFF for Oragenics?
Oragenics all-time high TTM cash flow from financing activities is $39.65 M
What is Oragenics TTM CFF year-on-year change?
Over the past year, OGEN TTM cash flow from financing activities has changed by +$5.78 M (+2034.95%)